Redeye comments on I-Tech’s Q4 figures figures missing our expectations across the board.
- Adj. EBIT -21% vs ABGSC, -21% vs FactSet consensus - Consensus to cut EBIT by 5% - Staff reduction...
- Sales -23% and adj. EBIT SEK -7m vs. consensus - Elevated temp.
Redeye comments on Sleep Cycle's Q4 2023 report, which continued to show a q/q growth rate in the su...
Finnair reports Q4 on Feb 14. In our view this year’s summer season will again lift earnings as volu...
CapMan’s Q4 results were below expectations, with revenue of EUR 14.
Redeye states sales and adjusted EBITDA were better-than-expected and Sivers achieved its adjusted E...
Redeye comments on the Q4 report released earlier this morning.
Redeye updates Spago Nanomedical after reporting the Q4 result.
Marimekko reports its Q4 results on 15th of February.
- Sales -1%, adj. EBITA +1% vs. cons, -6% org. sales - Cons '24e EBITA to come down 2-4% - Slightly ...
Redeye’s view on the Q4 report. The organic growth was way above our and the market’s expectations.
CapMan's Q4 fell short of LSEG Data & Analytics consensus expectations, partly explained by adjustme...
Redeye updates on Embracer ahead of Q3-results (due 15 February) where growth will be driven by the ...
- Sales +5% y-o-y, EBITA +38% y-o-y - We lift '24e-'25e EBITA by 3% on 1% lower opex - 10x '24e EV/E...
Vaisala will report Q4 earnings on February 14th. We expect solid performance in W&E while IM contin...
On Thursday, February 15, Starbreeze will publish its year-end report.
Redeye views the announced large acquisition of Prido as positive and increase both the near-term es...
- We expect 22% organic growth in Q4 and EBIT up 35% y-o-y - 2024e-25e EBIT down 6% as FX shaves 2% ...
CapMan's net sales in Q4 amounted to EUR 14.1m, below our estimates and below consensus (EUR 15.
